Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response.

Lappegård KT, Enebakk T, Thunhaug H, Ludviksen JK, Mollnes TE, Hovland A.

J Clin Lipidol. 2016 Nov - Dec;10(6):1481-1487. doi: 10.1016/j.jacl.2016.09.001. Epub 2016 Sep 13.

PMID:
27919366
2.

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.

Lappegård KT, Enebakk T, Thunhaug H, Hovland A.

Atherosclerosis. 2016 Aug;251:119-123. doi: 10.1016/j.atherosclerosis.2016.06.015. Epub 2016 Jun 9.

PMID:
27318831
3.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.

N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

4.

Edoxaban versus warfarin in patients with atrial fibrillation.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators.

N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.

5.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.

Supplemental Content

Loading ...
Support Center